Atomic AI
Drug discovery company
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Biology
- SaaS
- Science
- Oyster Point, South San Francisco, CA
Jump to section
Company mission
To unleash the power of artificial intelligence on molecular structure to engineer RNA biology, creating medicines that can tackle diseases that were previously untreatable.
Our take
The creation of new drugs often relies on the discovery of previously unknown molecules. This may involve novel RNA structures that are able to target specific diseases. Atomic AI is a biotechnology company that combines machine learning with structural biology to unlock RNA drug discovery.
In this approach, the company is creating an entirely new field of drug discovery. Its platform can accurately predict 3D RNA structures, essentially creating effective and safer small molecules to be used against currently undruggable diseases.
The company launched in 2023 with strong funding that is being invested into accelerating growth, expanding operations and broadening its business reach. Its vision to revolutionise an industry is an exciting proposition, especially when considering its early support.
Freddie
Company Specialist at Welcome to the Jungle
Funding (2 rounds)
Jan 2023
$35m
SERIES A
Jan 2021
$7m
SEED
Total funding: $42m
This company has top investors
Leadership
Raphael Townshend
(CEO & Founder)Obtained a PhD in Computer Science from Stanford University. Previously underwent Internships for DeepMind, Scaled Inference, and Google.